

## ACE under Stress: A Comprehensive Review of Stability Indicating Chromatographic Methods

Meena P V\*, Najah P A, Saranya Mohan, Shifa Mammed Kutty K M, Wafa T  
*Department of Pharmaceutical Analysis, Al Shifa college of pharmacy (Kerala University of Health science),  
Perithalmanna, Malappuram  
Corresponding Author; Meena P V*

Date of Submission: 05-09-2025

Date of Acceptance: 15-09-2025

### ABSTRACT

Angiotensin-converting enzyme (ACE) inhibitors are still the cornerstone in the treatment of cardiovascular diseases and hypertension, but their wide range of chemical structures such as sulfhydryl, carboxylate, phosphate, and ester prodrugs make them susceptible to stress degradation. Stability- indicating chromatographic methods (SIMs) are thus critical for separating intact drug molecules from their hydrolytic, oxidative, hydrolytic, oxidative, photolytic, and thermal degradation products. This review gives an extensive account of published SIMs for ACE inhibitors that include high- performance liquid chromatography (HPLC), ultra- high- performance liquid chromatography (UHPLC), high- performance thin- layer chromatography (HPTLC), and hyphenated LC- MS methods. Described studies are critically discussed in relation to forced degradation approaches, chromatographic selectivity, validation parameters, and regulatory compliance with ICH Q1 A(R2), Q2(R2), and Q14 guidelines. Comparative discussion focuses on prevalent routes of degradation like ester hydrolysis to active acids, diketopiperazine formation and oxidative dimerization of sulfhydryl groups. Trends involve increased utilization of design- of- experiments (DOE), peak- purity determination by PDA or MS, and the use of greener mobile phases. By distilling methodological progress and pitfalls, this review hopes to provide a handy guide for analysts designing sound, regulatory compliant stability- indicating assays for ACE inhibitors in bulk and pharmaceutical preparations.

**KEY WORDS:** ACE inhibitors, stability- indicating methods, forced degradation, HPLC, UHPLC, HPTLC, LC- MS, ICH guidelines.

### I. INTRODUCTION

Angiotensin- converting enzyme (ACE) inhibitors are some of the most common antihypertensive drugs, also used in heart failure, post- myocardial infarction, and diabetic

nephropathy. The class is structurally chemically heterogeneous, ranging from sulfhydryl- containing derivatives (captopril) to dicarboxylates (enalapril, lisinopril, quinapril), phosphinates (fosinopril), and prodrug esters (ramipril, perindopril, trandolapril, cilazapril, benazepril). Their clinical effectiveness is balanced by a well- documented stability to degradation under stress conditions. Ester- based prodrugs are hydrolysed to active acidic forms (e.g., enalapril enalaprilat), thiol analogs such as captopril are easily oxidized to disulfides, and lisinopril would preferentially cyclize to diketopiperazine (DKP) under heat or base stress [1-3].

Pharmaceutical formulations should be examined using validated stability- indicating techniques (SIMs) capable of readily separating the active pharmaceutical ingredient (API) from its possible impurities and degradation products, as the International Council of Harmonisation guidelines state (ICH Q1A(R2), Q2(R2)) [4,5]. The available analytical methods of chromatographic techniques- specifically high- performance liquid chromatography (HPLC), ultra- high- performance liquid chromatography (UHPLC), and high- performance thin- layer chromatography (HPTLC)- are used most commonly for SIM development of ACE inhibitors because they have better selectivity and compatibility with photodiode array (PDA) and mass spectrometric detection [6,7].

Forced degradation studies are the basis of stability- indicating method (SIM) development, in which ACE inhibitors are subjected to hydrolytic, oxidative, thermal, and photolytic stress to generate degradation products that challenge the selectivity of the method. For example, a number of HPLC- based stability- indicating assays for enalapril (both bulk drug and dosage forms) effectively resolve enalaprilat and its oxidative by- products [8]. Similarly, validated chromatographic methods for lisinopril and ramipril have been described, illuminating degradation mechanisms that reflect realistic storage and formulation conditions [9,10].

In light of clinical importance of ACE inhibitors and the regulatory requirement for stability and shelf-life testing, a thorough review of chromatographic stability- indicating methods (SIMs) for these drugs is appropriate and useful. This review attempts to synthesize described

analytical methods, evaluate degradation mechanisms and chromatographic separation, determine typical practice in validation and conformance to regulatory requirements, and provide advice on enhancing subsequent method development.

Drug	Chemical nature	Prodrug/ active form	Half-life	Primary clinical use	Key notes
Enalapril	Dicarboxylate derivative	Prodrug → Enalaprilat	11	Hypertension, CHF	Widely used in single & combination therapies
Lisinopril	Dicarboxylate derivative	Active drug	12	Hypertension, CHF, post- MI	Water soluble, not a prodrug; long- acting
Ramipril	Dicarboxylate derivative	Prodrug → Ramiprilat	13-17	Hypertension, CHF, CV risk reduction	High tissue penetration; cardioprotective
Perindopril	Dicarboxylate derivative	Prodrug → Perindoprilat	3-10	Hypertension, stable CAD	Once- daily dosing, vascular protective effects
Quinapril	Dicarboxylate derivative	Prodrug → Quinaprilat	2-5	Hypertension, CHF	Ester prodrug, hepatically activated
Fosinopril	Phosphinate ester	Prodrug → Fosinoprilat	11-12	Hypertension, CHF	Dual hepatic & renal elimination
Benazepril	Dicarboxylate derivative	Prodrug → Benazeprilat	10-12	Hypertension	Common in fixed dose combination
Trandolapril	Dicarboxylate derivative	Prodrug → Trandolaprilat	15-24	Hypertension, LV dysfunction	Long half-life, suitable for once- daily dosing
Moexipril	Dicarboxylate derivative	Prodrug → Moexiprilat	2-9	Hypertension	Food effect on absorption; less commonly used
Captopril	Sulfhydryl- containing	Active drug	2	Hypertension, CHF, diabetic nephropathy	First ACE inhibitor, short- acting

## II. STABILITY INDICATING CHROMATOGRAPHIC TECHNIQUES

Stability-indicating chromatographic analytical procedures are validated analytical methods meant to effectively separate and quantify active pharmaceutical ingredients (APIs) even in the presence of impurities, excipients, or degradation products. Such methods are developed by performing forced degradation studies under stress conditions like acidic, basic, oxidative, thermal, and photolytic conditions, as suggested by

ICH Q1A (R2). Their main function is to verify specificity, preventing interference from degradation by-products in the drug assay. Frequently used methods are HPLC, HPTLC, and GC, appreciated for their sensitivity and accuracy. Such procedures are crucial for determining stability profiles, quality control, and regulatory compliance, hence ensuring the safety, purity, and efficacy of pharmaceutical products throughout shelf life.

### Role of stability indicating HPLC in pharmaceutical analysis

Stability-indicating methods (SIMs) are analytical methods that can precisely quantify active pharmaceutical ingredients regardless of the degradation products, impurities, or excipients present. Of the chromatographic tools available, High-Performance Liquid Chromatography (HPLC) is most widely used due to its higher resolution, sensitivity, and reproducibility. To develop a stability-indicating HPLC method, the drug undergoes forced degradation studies including acidic, alkaline, oxidative, photolytic, and thermal stress following ICH Q1A (R2) guidelines. The stress conditions generate potential degradation products, which are separated and quantified to prove method specificity. Importance of these methods is that they can:

- Assess drug stability during formulation and fix shelf-life.
- Facilitate quality control by checking potency, purity, and safety.
- Comply with regulations, whereby organizations such as ICH and FDA require stability-indicating methods validated for drug approval.

In general, stability-indicating HPLC is a mainstay of pharmaceutical analysis to guarantee drugs continue to be effective and safe to use throughout their intended lifespan.

### High- Performance Liquid Chromatography method

A broad range of HPLC method of stability indicating of ACE inhibitors are available. The validated RP- HPLC stability- indicating assays for enalapril maleate have clearly resolved the parent compound from the principal degradation products such as enalaprilat and diketopiperazine under hydrolytic (acidic/alkaline), oxidative, thermal, and photolytic stress conditions. All of these methods meet the ICH validation criteria and exhibited excellent specificity, linearity with a correlation coefficient  $\geq 0.999$ , and accuracy ranging within 98-102%, making them suitable for routine quality control and stability monitoring of enalapril dosage forms [11-13]. Likewise, stability-indicating HPLC methods of development for lisinopril yield effective separation of the drug from its primary degradation products, diketopiperazine (DKP), and also from the excipients of the formulations. Forced degradation studies validate DKP formation under alkaline and thermal stress

conditions. The validated analytical techniques, as per ICH guidelines, demonstrate high specificity, accuracy (98-102%), and precision ( $\%RSD \leq 2$ ), validating their use for stability determination [14-15]. Stability- indicating HPLC methods for captopril are oriented to bypass its thiol- associated instability, frequently uses pre- column derivatization, ion- pair chromatography, or electrochemical detection for improved selectivity. Stress testing reveals oxidative degradation to disulfide dimers and sulfoxides. Validated procedures ensure reliable separation, precision and ruggedness, justifying their use in routine stability evaluation [16-17]. For ramipril, stability-indicating HPLC methods efficiently differentiate the native drug from its major degradant, ramiprilat, as well as other hydrolytic and oxidative products. Degradation tests show its susceptibility to moisture, high temperature, and light. Method validation also ensures specificity, accuracy ( $\square 100\%$ ), and precision within ICH standards, ensuring their suitability for stability monitoring [18-19]. Stability- indicating HPLC assays of perindopril can differentiate the parent drug from its major hydrolytic degradant, perindoprilat, as well as from oxidative and photolytic by- products. The methods, internally validated according ICH guidelines, show high accuracy, precision, and specificity, whereas LC- MS- based techniques offer improved sensitivity for degradant detection [20]. Like that, stability- indicating HPLC methods for benazepril also allow discrimination of the drug from its significant hydrolytic product, benazeprilat, and other stress degradation impurities. Forced degradation using acidic, alkaline, oxidative and light stress reaffirms the selectivity of these tests, with validation indicating good accuracy (around 98-102%) and precision ( $\%RSD \leq 2$ ) in support of their application in stability assessment [21- 22]. Validated stability-indicating HPLC procedures for quinapril provide sharp separation of the parent drug from its major hydrolytic product, quinaprilat, along with other degradation impurities formed under stress. Acidic, alkaline, and oxidative forced degradation studies establish method selectivity, whereas validation proves to be accurate between 98-102% and precise within  $\%RSD \leq 2$ , and thus the assays are fit for stability evaluation and regular quality control [23-24]. Fortrandolapril, stability-indicating RP-HPLC approaches efficiently distinguish the drug from several hydrolytic and oxidative degradants. Accelerated stress test points to vulnerability towards alkaline and peroxide stress, and confirmed findings ascertain specificity, accuracy

(98-102%), and precision (% RSD $\leq$ 2), which warranty stability study reliability in drug formulations [25-26]. Stability- indicating HPLC tests for cilazapril use RP- C18 columns with acetonitrile- buffer mobile phases, ensuring efficient resolution of the drug from its hydrolytic

and cyclic cleavage products. Stress studies show its susceptibility to moisture and higher temperature, and validation findings authenticate the procedures to be specific, accurate, and precise for evaluation of stability in bulk drug and dosage forms [27-28].

Literature Review Table: Overview of Stability- indicating HPLC methods

Drug	Representative HPLC conditions	Forced degradation & major degradants	Forced degradation & major degradants	Reference
Enalapril / Enalapril maleate	C18 phosphate buffer + ACN/MeOH	Acid/base hydrolysis → enalaprilat & diketopiperazine (DKP); oxidative (H <sub>2</sub> O <sub>2</sub> ) → Oxidized products; photolysis & thermal degradation	Linearity r $\geq$ 0.999; accuracy 98–102%; precision %RSD $\leq$ 2; PDA peak purity confirmed	11-13
Lisinopril	C18; buffer + ACN	Hydrolysis & cyclization → DKP; oxidative degradation a LC–MS used for degradant ID	Specificity (no excipient interference); accuracy 98–102%; precision $\leq$ 2% RSD	14-15
Captopril	C8/C18; ion-pair mobile phase (pentane sulfonate)	Oxidation → disulfidedimers, sulfoxides; base hydrolysis also possible	validated sensitivity; DoE/QbD applied; precision improved with derivatization/ECD	16-17
Ramipril	C18; phosphate buffer + ACN/MeOH	Hydrolysis →ramiprilat; oxidative & photolytic degradation	Specificity (baseline separation from ramiprilat); accuracy ~100%; %RSD $\leq$ 2; robustness sometimes via DoE	18-19
Perindopril	C18; buffer + ACN	Hydrolysis perindoprilat; oxidative & photolytic degradation	Specificity, linearity, accuracy;	20
Benazepril	C18; buffer + organic (MeOH or ACN)	Hydrolysis benazeprilat; oxidative stress (H <sub>2</sub> O <sub>2</sub> ) → oxidized products;	Validated per ICH: specificity, linearity, accuracy, precision; suitable for bulk & dosage	21-22
Quinapril	C18; buffer + ACN	Hydrolysis → quinaprilat;	Acceptable accuracy,	23-24

		acid/base hydrolysis; oxidative stress products	precision, specificity;	
Trandolapril	C18 phosphate buffer + ACN	Upto 6 oxidative degradants under H <sub>2</sub> O <sub>2</sub> ; hydrolytic (alkaline > acid); mild photolysis	Specificity & linearity validated; robustness via factorial DoE; accuracy/precision per ICH	25-26
Cilazapril	C18; phosphate buffer + ACN	hydrolysis → cilazaprilat; cyclic degradants reported;	Validated for specificity, linearity, accuracy, precision; applied to tablets & suspensions	27-28

**Role of HPTLC stability- indicating in pharmaceutical analysis**

Stability-indicating High-Performance Thin Layer Chromatography (HPTLC) is a powerful technique for pharmaceutical analysis, which can separate and quantify drugs together with their degradation products formed under stress conditions like acidic, alkaline, oxidative, thermal, and photolytic conditions. It has high specificity to quantify the drugs without interference from degradants or excipients. Thanks to its cost-effectiveness, speed, and ability to analyse several samples at once, HPTLC is commonly used in routine stability testing, determination of stability profiles, shelf-life determination, and compliance with regulatory requirements—eventually assuring the safety, efficacy, and purity of drugs.

**High- Performance Thin Layer Chromatography method**

A wide range of stability indicating HPTLC methods have been explored for ACE inhibitors. Barsagade A. et al. developed simultaneous estimation of enalapril maleate and losartan potassium stability-indicating HPTLC

method, which successfully separated analytes from degradants. Enalapril underwent acidic, basic, and thermal degradation, while losartan was photolytically degraded, with the method validated according to ICH guidelines [29]. Dewani Mohit G et al. expanded stability-indicating HPTLC perindopril erbumine on silica gel plates with a mobile phase containing dichloromethane–methanol–glacial acetic acid and detection at 215 nm. The procedure separated drug peaks from degradative peaks under different stress conditions and was validated according to ICH guidelines [30]. Dr. Anjana et al. developed and validated an HPTLC method of simultaneous estimation of lisinopril dihydrate and cilnidipine with good linearity, sensitivity, and precision. The abstract is not stated to confirm forced degradation studies, so its complete stability-indicating character is uncertain [31]. Bhoire et al. have established a validated stability-indicating HPTLC method for simultaneous estimation of perindopril and indapamide in bulk and in tablets. The technique could efficiently separate drugs from degradations under stress conditions to meet ICH validation criteria [32].

Literature Review Table: -Overview of Stability- indicating HPTLC methods

Drug	Representative HPLC conditions	Stress Conditions & Findings	Validation	Reference
Enalapril maleate + Losartan potassium	Silica gel 60 F254	Acid, base, thermal → enalapril degraded; photolysis → losartan degraded	Specific, accurate, acceptable LOD/LOQ, ICH compliant	29
Perindopril erbumine	Silica gel 60 F254; dichloromethane:methanol:glacial	Forced degradation: hydrolytic,	Specific, validated	30

	acetic acid	oxidative, thermal, photolytic	as per ICH Q1A(R2) & Q2(R1)	
Lisinopril dihydrate +Cilnidipine	Silica gel 60 F254	stability-indicating nature uncertain	Validated for linearity, precision, sensitivity	31
Perindopril +Indapamide	Silica gel 60 F254	Forced degradation under various stress conditions	Specific, accurate, ICH guideline compliant	32

### III. STABILITY INDICATING HYPHENATED CHROMATOGRAPHIC METHODS

Stability-indicating chromatographic hyphenated techniques combine separation methods with spectroscopic or mass spectrometric detection in order to determine drugs and their degradation products with high sensitivity. They include forced degradation under acidic, alkaline, oxidative, thermal, and photolytic stress according to ICH Q1A(R2) guidelines. Methods like LC-MS, LC-MS/MS, GC-MS, LC-NMR, and LC-FTIR allow both structural characterization and quantification. These procedures are crucial in determining degradation pathways, impurities, and stability profiles of drugs. They provide compliance with regulation, enhance quality control, and assure drug safety and effectiveness.

#### Hyphenated techniques

Roskar et al. (2009) employed LC-MS in the investigation of the stability of a novel ACE inhibitor, xPRIL, and determined two primary degradation pathways affected by temperature and pH. The study also contrasted the degradation kinetics of xPRIL with that of enalapril and perindopril, providing insight into ACE inhibitor stability profiles.[33]

### IV. CONCLUSION

Stability-indicating chromatographic methods are of central importance in pharmaceutical analysis for ensuring the quality, safety, and efficacy of drug substances and formulations during their shelf life. HPLC remains the gold standard technique with extraordinary resolution, sensitivity, and versatility for the determination and quantitation of drugs and their degradation products. HPTLC is a useful supplementary tool, offering a fast, cost-effective,

and high-throughput alternative well adapted to routine stability testing and comparative studies. More sophisticated hyphenated techniques, e.g., LC-NMR, yield conclusive structural data on degradation products, especially where mass spectrometric information might be limiting. Together, these procedures meet not only ICH and regulatory demands but also produce extensive information on stability profiles, degradation routes, and impurity identification. The integration of traditional and hyphenated chromatographic approaches enhances the validity of stability studies and enhances the creation of safe, effective, and high-quality drugs.

### REFERENCES

- [1]. Carlucci G. Analysis of ACE inhibitors in pharmaceutical dosage forms. *J Pharm Biomed Anal.* 1993;11(7):593-601.
- [2]. Regulska E, Nowak A, Podsadni P, Dąbrowska M, Chmiel K, Żarowska B, et al. Solid-state stability and degradation pathways of ramipril. *Molecules.* 2014;19(12):20470-85.
- [3]. Beasley CA. Development and validation of a stability-indicating HPLC method for lisinopril. *J Pharm Biomed Anal.* 2005;39(3-4):509-18.
- [4]. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
- [5]. International Council for Harmonisation (ICH). ICH Q2(R2): Validation of analytical procedures. Geneva: ICH; 2023.
- [6]. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability-indicating methods: a review. *J Pharm Anal.* 2014;4(3):159-65.

- [7]. Bakshi M, Singh S. Development of validated stability-indicating assay methods: critical review. *J Pharm Biomed Anal.* 2002;28(6):1011-40.
- [8]. Seshadri RK, Reddy BSR, Suryanarayana MV, Reddy GO. Stability-indicating RP-HPLC method for enalapril maleate. *Sci Pharm.* 2012;80(3):749-60.
- [9]. Beasley CA. Development and validation of a stability-indicating HPLC method for lisinopril and its degradation product. *J Pharm Biomed Anal.* 2005;39(3-4):509-18.
- [10]. Regulska E, Stanisiz B, Nowakowska E, Koba M. Stability-indicating studies on ramipril. *Molecules.* 2014;19(12):20470-85.
- [11]. Mohan S, Rao AL, Reddy KS. Validation of stability indicating HPLC method for the determination of enalapril maleate in tablet formulations. *Int J Pharm Pharm Sci.* 2011;3(Suppl 5):180-3.
- [12]. Al-Omari MM, Abdelah MK, Badwan AA, Jaber AM. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. *J Pharm Biomed Anal.* 2001;25(5-6):893-902.
- [13]. Nataraj KS, et al. Analytical method development and validation of stability indicating RP-HPLC method for assay and related substances of enalapril maleate tablets. *Int J Pharm Biol Sci.* 2018;8(3):234-240.
- [14]. Beasley CA, Shaw J, Zhao Z, Reed RA. Development and validation of a stability-indicating HPLC method for determination of lisinopril, its degradation product and parabens in the lisinopril extemporaneous formulation. *J Pharm Biomed Anal.* 2005;37(3):559-567.
- [15]. De Diego M, Soto J, Mennickent S. Stability-indicating LC method for the simultaneous determination of lisinopril and hydrochlorothiazide. *J Chromatogr Sci.* 2014;52(10):1193-7.
- [16]. Ahmed S, Rahman M, Hossain M, et al. Stability-indicating HPLC method for captopril through pre-column derivatization with Pd(II). *J Liq Chromatogr Relat Technol.* 2006;29(4):521-32.
- [17]. Pramari Y, Das Gupta V, Bethea C. Stability of captopril in some aqueous systems. *J Clin Pharm Ther.* 1992;17(3):185-9.
- [18]. Gobardhan R, Sharma P, Kumar A, et al. Stability-indicating RP-HPLC method for determination of ramipril in drug substance and marketed formulation. *Int J Front Sci Technol.* 2013;1(2).
- [19]. Regulska K, Musiał J, Stanisiz BJ. Solid-state stability profiling of ramipril to optimize its quality, efficiency, and safety. *Pharmaceutics.* 2021;13(10):1607.
- [20]. Duraisamy K, Jaganathan KS, Krishna MV. Method development and validation of HPLC tandem/mass spectrometry for quantification of perindopril arginine and amlodipine besylate combination in bulk and pharmaceutical formulations. *Res Pharm Sci.* 2017;12(4):307-14.
- [21]. Chhalotiya UK. Stability-indicating LC method for the estimation of benazepril HCl and hydrochlorothiazide in pharmaceutical dosage form. *J Chromatogr Sep Tech.* 2014;5(2).
- [22]. Soumya S, Kumar R, Sharma P, et al. Method development and validation of a stable HPLC method to measure benazepril hydrochloride in both bulk and pharmaceutical dosage forms. *J Emerg Technol Innov Res.* 2024;11(6).
- [23]. De Diego M, Soto J, Mennickent S. A validated stability-indicating LC method for simultaneous determination of quinapril and hydrochlorothiazide in pharmaceutical samples. *Cent Eur J Chem.* 2014;12(4):470-5.
- [24]. Taj SA, Kumar SR. Stability-indicating RP-HPLC method development and validation for simultaneous analysis of quinapril and hydrochlorothiazide in bulk and tablet dosage form. *Int J Sci Res.* 2014;3(7).
- [25]. Dantu DR, Rao V, Kumar P, et al. Stress degradation studies ontrandolapril and development of a stability-indicating HPLC assay method for pharmaceutical dosage form. *Anal Chem Indian J.* 2009;8(2).
- [26]. Al-Hawash LA, Shakya AK, Saleem ML. Stability-indicating HPLC determination oftrandolapril in bulk drug and pharmaceutical dosage forms. *Int J Anal Chem.* 2015;2015:820517.
- [27]. Paszun SK, Stanisiz B, Pawłowski W. Rapid and simple stability-indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison

- with classic and derivative spectrophotometric methods. *Acta Pol Pharm.* 2012;69(2):193-201.
- [28]. Paszun SK, Stanis B, Pawłowski W. Rapid and simple stability-indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods. *Acta Pol Pharm.* 2012;69(2):193-201.
- [29]. Barsagade A, Kakde R. Development of validated specific stability-indicating HPTLC method for simultaneous estimation of enalapril maleate and losartan potassium in its combined dosage form. *Asian J Chem.* 2016;28:1118-22.
- [30]. Dewani MG, et al. Development and validation of stability-indicating HPTLC method for determination of perindopril erbumine. *Int Res J Pharm.* 2010;1(12):315-22.
- [31]. Anjana Devi D, et al. Development and validation of stability-indicating HPTLC methods for the estimation of antihypertensive drugs (lisinopril dihydrate and cilnidipine). *Afr J Biomed Res.* 2024;27(1S):174-83.
- [32]. Bhoire U, et al. Development and validation of stability-indicating HPTLC method for the estimation of perindopril and indapamide. *Int J Pharm Pharm Sci.* 2014;6(7):621-5.
- [33]. Roskar R, Gartner A, Kogej K, Kmetec V. Stability of new potential ACE inhibitor in aqueous solutions of different pH. *Int J Pharm.* 2009;356(1-2):200-5.